Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ningxia Tianren Goji Biotechnology has commercialized patented technologies for extracting high-purity Lycium barbarum glycopeptides. Their LbGp compounds are integrated into a range of health food, supplement, and specialty dietary products, and the company was awarded for innovation in plant extract products in 2019. Clinical results per se are not reported, as the focus remains on health food, not pharmaceuticals. Their LbGp extraction platform is recognized for maintaining bioactivity through advanced membrane separation and freeze-drying methods.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ningxia Tianren Goji Biotechnology.